Get the Stockscreener App
6.135
0.89%
-0.055
Diamedica Therapeutics Inc stock is traded at $6.135, with a volume of 31,407.
It is down -0.89% in the last 24 hours and up +6.88% over the past month.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
See More
Previous Close:
$6.19
Open:
$6.19
24h Volume:
31,407
Relative Volume:
0.31
Market Cap:
$264.69M
Revenue:
-
Net Income/Loss:
$-19.90M
P/E Ratio:
-11.58
EPS:
-0.53
Net Cash Flow:
$-19.80M
1W Performance:
+6.51%
1M Performance:
+6.88%
6M Performance:
+88.77%
1Y Performance:
+97.90%
1-Day Range:
$6.095
$6.30
1-Week Range:
$5.6101
$6.40
52-Week Range:
$2.14
$6.41
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Name
Diamedica Therapeutics Inc
Sector
Industry
Phone
(763) 496-5454
Address
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
6.13 | 264.69M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.99 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.58 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.42 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.27 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Jun-22-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-09-21 | Initiated | Oppenheimer | Outperform |
| Feb-17-21 | Initiated | ROTH Capital | Buy |
| Oct-30-20 | Initiated | Guggenheim | Buy |
| Jul-08-20 | Initiated | Maxim Group | Buy |
| Apr-30-19 | Initiated | Dougherty & Company | Buy |
| Mar-05-19 | Initiated | Lake Street | Buy |
View All
Diamedica Therapeutics Inc Stock (DMAC) Latest News
DiaMedica Therapeutics (NASDAQ:DMAC) Trading Down 1.5%Here's Why - MarketBeat
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Update - MarketBeat
DiaMedica Therapeutics: Interesting Work In Treating Ischemic Stroke - Seeking Alpha
Geode Capital Management LLC Purchases 70,070 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
Individual investors are DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) biggest owners and were hit after market cap dropped US$43m - Simply Wall St
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 28.4% in December - Defense World
Diamedica Stock Soars to 52-Week High, Hits $6.41 - Investing.com
Individual investors are DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) biggest owners and were hit after market cap dropped US$26m - Yahoo Finance
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Declines By 12.2% - MarketBeat
Diamedica Stock Soars to 52-Week High, Reaching $5.74 - Investing.com
Diamedica Stock Soars to 52-Week High, Reaching $5.74 By Investing.com - Investing.com UK
DiaMedica Therapeutics (NASDAQ:DMAC) Trading 0.6% HigherHere's What Happened - MarketBeat
DiaMedica Therapeutics (NASDAQ:DMAC) Trading 0.6% Higher – Should You Buy? - Defense World
Amneal to Participate at Upcoming Investor Conferences - Business Wire
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia - BioSpace
DiaMedica Therapeutics management to meet virtually with Lake Street - Nasdaq
DiaMedica Forms Elite Scientific Advisory Board for Preeclampsia Treatment Development - StockTitan
Sirius Therapeutics to Present Data from Its Phase 1 Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders at the 66th ASH Annual Meeting and Exposition - Business Wire
DMAC Stock Soars to 52-Week High, Hits $4.95 Amid Bullish Run - Investing.com
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation - Simply Wall St
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - MarketBeat
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2024 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Reports Q3 2024 Financial Results - TipRanks
DMACDiaMedica Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia - BioSpace
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results - BioSpace
DiaMedica (DMAC) to Present at Craig-Hallum Conference: Spotlight on DM199 Stroke Treatment | DMAC Stock News - StockTitan
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference - Business Wire
DiaMedica Therapeutics (DMAC) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
CRH plc (the "Company") Form 10-Q for the quarterly period ended September 30, 2024 - Business Wire
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 - BioSpace
Blue Trust Inc. Makes New Investment in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Large Growth in Short Interest - MarketBeat
Best Momentum Stocks to Buy for October 14th - Yahoo Canada Finance
Head to Head Contrast: DiaMedica Therapeutics (NASDAQ:DMAC) versus Provectus Biopharmaceuticals (OTCMKTS:PVCT) - Defense World
DiaMedica shares maintain Buy rating from H.C. Wainwright - Investing.com
DiaMedica shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com South Africa
DiaMedica gets SAHPRA approval for Phase II preeclampsia treatment trial - Yahoo Finance
DiaMedica advances preeclampsia treatment with trial approval By Investing.com - Investing.com South Africa
DiaMedica advances preeclampsia treatment with trial approval - Investing.com India
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
Research Analysts Offer Predictions for DiaMedica Therapeutics Inc.'s Q3 2024 Earnings (NASDAQ:DMAC) - MarketBeat
KaliVir Immunotherapeutics Doses First Patient in Phase 1/1b Trial of VET3-TGI for Incurable, Advanced, Solid Tumors - Business Wire
Diamedica Therapeutics Inc Stock (DMAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Diamedica Therapeutics Inc Stock (DMAC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STAHLBERG JAN | 10% Owner |
Jun 28 '24 |
Buy |
2.50 |
1,200,000 |
3,000,000 |
5,221,608 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):